Exploring a Revolutionary Non-Invasive Treatment
HistoSonics has successfully treated the first patients in the GANNON trial, a feasibility study using its novel histotripsy technology. The trial targets patients with inoperable pancreatic adenocarcinoma, focusing on unresectable locally advanced (Stage 3) and limited metastatic (Stage 4) disease.
Key Details of the Trial
- Technology: Histotripsy uses focused ultrasound to non-invasively destroy tumor tissue and surrounding fibrotic barriers.
- Trial Scope: Up to 30 patients are participating at Sant Pau Hospital in Barcelona, Spain, under Dr. Santiago Sánchez Cabús.
- Goals: Evaluate the safety of histotripsy and optimize its potential to treat advanced pancreatic tumors.
Addressing a Critical Need
Pancreatic cancer is one of the deadliest cancer types, with a 5-year survival rate of just 13% and limited treatment options.
- Challenges: Dense fibrotic tissue surrounding tumors often blocks traditional therapies.
- Impact: Fewer than 20% of patients are eligible for surgery due to late diagnosis.
Promising Potential
“Histotripsy offers a unique mechanism targeting both tumors and fibrotic tissue, giving hope to patients previously deemed untreatable,” said Dr. Joan Vidal-Jove, Medical Director of HistoSonics.
CEO Mike Blue emphasized the broader mission:
“Our goal is to extend histotripsy to multiple tumor types, improving outcomes for patients and families.”
Looking Ahead
The Edison System, central to this study, remains investigational, but early results from the GANNON trial may pave the way for expanded applications in cancer treatment.
Stay informed with MEDWIRE.AI for updates on groundbreaking technologies shaping the future of oncology care.
